p53 gene therapy - Shenzhen SiBiono GeneTech

Drug Profile

p53 gene therapy - Shenzhen SiBiono GeneTech

Alternative Names: Gendicine; p53 gene therapy - SiBiono; rAD-p53 - Shenzhen SiBiono GenTech; Recombinant Ad-p53 anti-cancer injection - Sibiono

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shenzhen SiBiono GeneTech
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Liver cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in India (Intratumoural, Injection)
  • 28 Apr 2015 Shenzhen SiBiono GeneTech plans a phase II trial for Ovarian Cancer, fallopian tube cancer and peritoneal cancer in China (NCT02435186)
  • 24 Apr 2015 Shenzhen SiBiono GeneTech plans a phase II trial for Malignant pleural effusion in China (NCT02429726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top